Sarepta Therapeutics (SRPT) to Release Earnings on Wednesday

Sarepta Therapeutics (NASDAQ:SRPT) will issue its quarterly earnings data after the market closes on Wednesday, May 1st. Analysts expect the company to announce earnings of ($0.11) per share for the quarter.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Wednesday, February 28th. The biotechnology company reported $0.47 EPS for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.50. The business had revenue of $396.80 million during the quarter, compared to the consensus estimate of $387.18 million. Sarepta Therapeutics had a negative net margin of 43.11% and a negative return on equity of 18.97%. The company’s quarterly revenue was up 53.6% compared to the same quarter last year. During the same period in the previous year, the firm posted ($1.24) earnings per share. On average, analysts expect Sarepta Therapeutics to post $2 EPS for the current fiscal year and $7 EPS for the next fiscal year.

Sarepta Therapeutics Trading Up 3.1 %

Shares of NASDAQ SRPT traded up $3.87 during midday trading on Thursday, reaching $128.12. 400,903 shares of the stock were exchanged, compared to its average volume of 976,503. The company has a market capitalization of $12.03 billion, a P/E ratio of -20.61 and a beta of 0.94. Sarepta Therapeutics has a 52-week low of $55.25 and a 52-week high of $159.89. The company has a current ratio of 3.95, a quick ratio of 3.45 and a debt-to-equity ratio of 1.32. The stock has a 50 day moving average price of $126.18 and a 200-day moving average price of $110.31.

Insiders Place Their Bets

In other Sarepta Therapeutics news, Director Stephen Mayo sold 3,135 shares of Sarepta Therapeutics stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $122.96, for a total transaction of $385,479.60. Following the completion of the transaction, the director now directly owns 6,621 shares of the company’s stock, valued at $814,118.16. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, Director Stephen Mayo sold 3,135 shares of Sarepta Therapeutics stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $122.96, for a total value of $385,479.60. Following the completion of the transaction, the director now directly owns 6,621 shares of the company’s stock, valued at $814,118.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Bilal Arif sold 2,000 shares of the business’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $128.84, for a total value of $257,680.00. Following the sale, the insider now directly owns 26,836 shares of the company’s stock, valued at $3,457,550.24. The disclosure for this sale can be found here. Insiders have sold 22,096 shares of company stock worth $2,739,419 over the last 90 days. Corporate insiders own 7.40% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on SRPT shares. Mizuho increased their price objective on shares of Sarepta Therapeutics from $130.00 to $145.00 and gave the stock a “buy” rating in a report on Wednesday, February 14th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $128.00 price objective on shares of Sarepta Therapeutics in a report on Thursday, February 29th. BMO Capital Markets assumed coverage on shares of Sarepta Therapeutics in a report on Wednesday, January 31st. They issued an “outperform” rating and a $170.00 price objective on the stock. Evercore ISI increased their target price on shares of Sarepta Therapeutics from $108.00 to $138.00 and gave the company an “in-line” rating in a research report on Tuesday, February 20th. Finally, Barclays increased their target price on shares of Sarepta Therapeutics from $141.00 to $185.00 and gave the company an “overweight” rating in a research report on Thursday, February 29th. Four research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to MarketBeat, Sarepta Therapeutics has an average rating of “Moderate Buy” and an average price target of $158.38.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.